Our Research
INTRODUCTION
InnovativeGx Laboratories background
- Specialty in Molecular Diagnostics
- Over thirty combined years of genetic laboratory research from our team of scientists
- Central laboratory located in San Antonio, Texas with support staff located throughout the U.S.
- Offering molecular services in pharmacogenetics (PGx), Respiratory Pathogens, and SARS coronavirus (COVID-19)
- FDA pipeline for many other molecular products
SARS CORONAVIRUS (COVID-19) TESTING
Various Testing Services available to the public
- Antigen Testing
- Viral RNA Testing (RT PCR)
- Antibody Testing
ANTIGEN TESTING
Antigen testing examines the viral proteins on the surface of the virus and is dose dependent on the amount of virus and timing of testing/virus infection.
REVERSE TRANSCRIPTION POLYMERASE CHAIN
REACTION (RT PCR) TESTING
- Viral RNA based testing (can detect one single strand of viral RNA)
- Transcribes RNA into a complementary DNA strand
- Molecular probes for specific sequences are used and areas are amplified using a fluorescent probe
- Analysis of signal will detect viral sequences and how much virus was in the original sample
- Over 99% accuracy of detection throughout the infection
- Not dose dependent on amount of virus in sample
ANTIGEN VERSUS RT PCR BASED TESTING
Antigen
- Examines the proteins on the virus
- Is dose dependent (too little virus = negative result)
- Up to 20-30% false negative results
RT PCR
- Examines the viral RNA in the virus itself
- Is not dose dependent (one strand of RNA = positive result)
- Up to 100% accuracy of results
PHARMACOGENOMIC TESTING OF PATIENTS (PGX)
- Pharmacogenomics (PGx) is the medical field of study that examines how a patients genetic sequences react and metabolize medicines
- Still in its infancy and growing in its research and clinical practice internationally
- Continuation of the U.S. Human Genome Project objectives from human mapping of gene sequences, to the study of gene functions, eventually using these genes and functions to help better medicine and treatments.
PHARMCOGENOMIC TESTING APPLICATIONS
- Cardiovascular
- Mental Health
- Cancer
- Adverse Drug Reactions (ADR)
- Pain Management
CARDIOVASCULAR PHARMACOGENOMICS
- CYP2C19 Variants
- Medications that are metabolized by CYP2C19
- Xarelto
- Coumadin
- Zocor
- Rythmol
- Apresoline
- Crestor
- Pronestyl, Procan, Procanbid
- Mevacor
- Plavix
- Lipitor
- Lopressor
- Quinaglute
- Coreg
- Aspirin
- Nebilet
- Lasix
- Bystolic
- Aldactone
- Inderal
COST BENEFIT ANALYSIS
Antiplatelet Therapy Effient (Prasugrel),
Plavix (Clopidogrel), Brilinta (Tricagrelor)
COST BENEFIT ANALYSIS OF CARDIO
VASCULAR MEDICATIONS
- Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
- Pharmacogenomics J. 2017 Oct; 17(5): 395–402.
COST BENEFIT ANALYSIS OF CARDIOVASCULAR MEDICATIONS
- CYP2D6 Variants
- Medications that are metabolized by CYP2D6
- Tegretol
- Celexa
- Cipralex
- Lexapro
- Anafranil
- Sinequan
- Quitaxon
- Aponal
- Tofranil
- Surmontil
- Elavil
- Valium
- Zoloft
- Asendin
- Prozac
- Sarafem
- Vivactil
- Effexor
- Norpramin
- Pertofrane
- Pamelor
- Luvox
- Paxil
- Seroxat
- Pristiq
COST BENEFIT ANALYSIS
- Assuming a test cost of USD$2,000 for pharmacogenetic testing, the model predicts a savings of USD$3,962 annually per patient with pharmacogenetic-guided depression medication management.
CANCER PHARMACOGENOMICS
- Thiopurine methyltransferase (TPMT) Enzyme Variants, dihydropyrimidine dehydrogenase (DPD), and CYP2C19
- Medications that are metabolized by TPMT Variants
Thiopurines
- Lanvis
- Purinethol
- Azasan
- Imuran
5-fluorouracil Platinum Agents
|
|
COST BENEFIT ANALYSIS
- For women with lymph node (ln)-positive, estrogen receptor-positive, and her2 (human epidermal growth factor receptor 2)-negative breast cancer (bca), current guidelines recommend treatment with both hormonal therapy and chemotherapy.
- The 21-gene Recurrence Score (rs) assay might be helpful in selecting patients with bca who can be spared chemotherapy when they have 1-3 positive lns and a lower risk of recurrence.
PAIN MANAGEMENT PHARMACOGENOMICS
- CYP2D6 Variants, Candidate Genes CYP3A4/A5, UGT2B7, ABCB1, ABCC3, SLC22A1
- Medications that are metabolized by CYP2D6 and candidate genes
- Codeine
- Tramadol
- Hydrocodone
- Oxycodone
EFFECTIVENESS OF PHARMACOGENETIC (CYP2D6)
ANALYSIS IN PAIN MANAGEMENT
- CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmaticclinical trial. Genetics in Medicine volume 21, pages1842– 1850(2019)
COST BENEFIT MILD PAIN PATIENT CASES
- Pharmacoeconomics of genotyping-based treatmentdecisions in patients with chronic pain
- PAIN Reports: September/October 2017 – Volume 2 – Issue 5 – p e615
COST BENEFIT MILD AND SEVERE PAIN PATIENT CASES
PAIN MANAGEMENT
- Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain
- PAIN Reports: September/October 2017 – Volume 2 – Issue 5 – p e615
COST BENEFIT SEVERE PAIN PATIENT CASES
- Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain
- PAIN Reports: September/October 2017 – Volume 2 – Issue 5 – p e615
ADVERSE DRUG REACTIONS PAIN MANAGEMENT
- Ziagen
- Tegretol
- Plavix
- Krystexxa
HOSPITAL ORGANIZATIONS AND MEDICAL CENTERS WITH ACTIVE PHARMACOGENETIC TESTING PROGRAMS FOR PATIENTS
- Harvard University Medical School
- Stanford Health Care
- St. Jude Children’s Research Hospital
- Vanderbilt University Medical Center
- Mayo Clinic
- Penn Medicine
- Duke University Medical Center
- University of North Carolina Medical Center
- Children’s Mercy Hospital
- Department of Veterans Affairs
- Brigham and Women’s Hospital
